Xalkori is still not recommended for ALK positive non-small cell lung cancer by nice final guidelines

September 29, 2013 12:11 source: Ding Xiangyuan UK National Health and Medical Quality Standards Agency (NICE) released the final use guidance plan for xalkori, a Pfizer drug for the treatment of anaplastic lymphoma kinase (ALK) - positive advanced non-small cell lung cancer, because it is not cost-effective, the drug is not recommended in the plan Xalkori, commonly known as crizotinib, is a tyrosine kinase inhibitor, which can inhibit the activity of tumor stimulating enzymes, especially the activity of anaplastic lymphoma kinase in some patients with non-small cell lung cancer Only 5% of these patients Xalkori is the first new drug to treat lung cancer approved by the US FDA in six years Its sales volume in the first half of this year is 120 million US dollars, and it will grow rapidly in the next few years When xalkori entered the UK market in December last year, nice recognized its efficacy, but cost-effectiveness was its biggest obstacle According to nice, the cost of xalkori for 30 days is £ 4689 and the cost of a course of treatment per patient is £ 51579 According to the agency's quality adjusted life year analysis (QALY), xalkori costs between £ 50000 and £ 100000, far more than the highest hospice price of £ 30000 Andrew Dillon, chief executive officer of nice, commented: "during the consultation on the final plan, Pfizer provided the Committee with further information for consideration, including the use plan of drugs for patients with NHS insurance at a lower price A revised cost-benefit analysis report of drugs was also submitted to the Committee for evaluation For different stages of non-small cell lung cancer patients, nice has a variety of recommended treatment options Although the independent committee has taken into account evidence that xalkori is effective in the treatment of ALK positive advanced non-small cell lung cancer, and Pfizer can offer a price discount, its cost-effectiveness is still not applicable to the NHS "Nice's decision not only affects the use of drugs in NHS in the UK, but also the NHS in other countries will pay close attention to the agency's decision Jonathan EMMS, Pfizer's UK executive director, said nice was stifling innovation by refusing or limiting 40% of new drug use last year Source address: http://www.pmlive.com/pharma'news/pfizers'xalkori'not'good'value'for'money, 'says'nice'505339